Louisiana Office of Public Health Laboratories	
Test Name	Hepatitis A IgM Antibody EIA
PHL Location	Office of Public Health Laboratory Baton Rouge
CPT Code	86709
Synonyms	Antibody to Hepatitis A Virus IgM , Anti-HAV IgM
Brief Description of Test	The MONOLISA™ Anti-HAV IgM EIA is an enzyme immunoassay (IgM antibody capture format) for use in the qualitative detection of IgM antibodies to hepatitis A virus (anti-HAV IgM) in human (adult and pediatric) serum. This assay is indicated for testing specimens from individuals who have signs and symptoms consistent with acute hepatitis. Assay results, in conjunction with other serological or clinical information, may be used for the laboratory diagnosis of individuals with acute or recent hepatitis A.
Possible Results	Nonreactive Borderline Reactive
Reference Range	Nonreactive
Specimen Type	Serum
Specimen Container(s):	Red top tubes, Marble top tubes, polypropylene vials
Minimum volume accepted:	220 μL
Collection Instructions	Specimens should only be collected by personnel that have been properly trained. Care should be taken during specimen collection and handling to avoid generation of aerosols. Blood should be collected in a plastic tube, such as a vacutainer, which does not contain an anticoagulant. The collection tube may or may not contain a serum separator. If collected in a tube without serum separator, serum must be aliquoted into screw cap tubes before shipment to laboratory. Depending on the type of collection tube, the amount of time it will take for the blood to clot could take up to 60 minutes. Separation of serum from cells should take place within 2 hours of collection to prevent erroneous test results according to NCCLS guidelines. Follow the package insert for the collection tube you use.

	Label specimen with Patient Name and a 2 nd unique identifier such as a chart number or medical record number. DOB is not considered unique.
	Complete a Lab Form 96 to accompany the serum sample. Lab submission form must be thoroughly completed with patient's first and last name, 2 nd patient identifier, gender, date of birth, date of collection, time of collection, test requested, and submitter's name, address, and contact number.
	Two unique identifiers MUST be recorded on the tube AND the Lab 96 form. A missing identifier on the tube will be an automatic rejection. If the identifiers are missing from the Lab 96 form, the submitter must be contacted and a new form with this information must be faxed back to the lab before testing will take place
	Transport specimen to laboratory as soon as possible after collection. Keep submission forms insulated from specimens.
	Specimens must be shipped refrigerated (2-8°C) and can be stored for up to 7 days.
Storage and Transport Instructions	For longer storage, serum should be poured into a sterile screw cap tube and be frozen at -20°C or colder. Frozen specimens must be shipped on dry ice and received at a temperature of -20°C or colder. If samples are frozen, document the date and time the sample was frozen.
Causes for Rejection	Unspun samples, tubes that contain less than 90% of the total drawing capacity (QNS), incorrect specimen type, or expired collection tubes must be rejected. Hyperhemolyzed specimens, contaminated specimens, hyperlipemic specimens, improper storage and improper transport temperature requirements are also reasons for rejection.
Limitations of the Procedure	Diagnosis of an infectious disease should not be established on the basis of a single test result. Detection of anti-HAV IgM does not necessarily imply an acute HAV infection due to the longevity of anti-HAV IgM. The detection of anti-HAV IgM can be useful for the differential diagnosis of hepatitis A from other forms of viral hepatitis. Any diagnosis should take into consideration the patient's clinical history and symptoms, as well as other laboratory data. Patients with specimens exhibiting borderline results should be retested at approximately two week intervals. A reactive anti-HAV IgM result does not exclude co-infection by another hepatitis virus. A nonreactive result does not exclude the possibility of infection with hepatitis A virus. Levels of Anti-HAV IgM may be below the cutoff in early infection. The performance of the MONOLISA TM Anti-HAV IgM EIA has not been established with immunosuppressed or immunocompromised patients, cord blood, neonatal specimens,

	cadaveric specimens, heat-inactivated specimens, or body fluids other than serum or plasma, such as saliva, urine, amniotic, or pleural fluids.
Interfering Substances	Heterophilic antibodies, bacterial contamination, hyperhemolysis, hyperlipemia
References	BioRad MONOLISA TM Anti-HAV IgM EIA package insert. EVOLIS TM Operator Manual
Additional Information	None
Release Date	03/15/2016

Warning: If you have printed a copy of this information please be advised that the Louisiana Office of Public Health Laboratories website and methods are updated on a regular basis. Please check the on-line version of this document to ensure you are relying on the most recent release.

LO.FM.GEN.043 V2 4 2013